Human Anti-HIV-1 gp120 Recombinant Antibody (clone BAT123) (CAT#: FAMAB-0177CQ)

Figure 1 BAT123 pharmacokinetics in hu-PBL-SCID mice

The monoclonal antibody BAT123 was injected intraperitoneally into four groups of mice (six animals per group) at doses of 5 mg/Kg (○), 10mg/Kg (●),20mg/Kg (□) ro mg/Kg (■). Blood was obtained from the tail wein on the days indicated and serum concentrations of BAT123 determined by quantitative ELISA. Error bars represent s.e.m.

Safrit, J. T., Fung, M. S., Andrews, C. A., Braun, D. G., Sun, W. N., Chang, T. W., & Koup, R. A. (1993). hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS (London, England), 7(1), 15-21.

Figure 2 PNTU, BAT12, and CGP 47 439 pharmacokinetics in hu-PBL-SCID mice challenged with HIV-1.

The monoclonal antibody PNTU(∆), BAT12(○), or CGP 47 439(□) was injected intraperitoneally into six hu-PBL-SCID mice at dosesof 40 mg/Kg. An hour later, the mice were inoculated intraperitoneally with 10 animal infectious doses of HIV-1 IIIB. Blood was obtained from the tail wein on the days indicated and serum cincentrations of the injected antibody determined by quantitative ELISA. Error bars represent s.e.m.

Safrit, J. T., Fung, M. S., Andrews, C. A., Braun, D. G., Sun, W. N., Chang, T. W., & Koup, R. A. (1993). hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS (London, England), 7(1), 15-21.

Figure 3 Neutralization of HIV-1 IIIB challenge stock by BAT123.

Ability of BAT123(○) or PNTU(□) to neutrelize infecticity of the HIV-1 IIIB challenge dtock was tested in the syncytium-forming assay using CEM-SS cells.

Safrit, J. T., Fung, M. S., Andrews, C. A., Braun, D. G., Sun, W. N., Chang, T. W., & Koup, R. A. (1993). hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS (London, England), 7(1), 15-21.

Figure 4 In vitro neutralization by BAT123.

Neutralization profiles of BAT123 against HIV-I strains LAI, SF2, JR -CSF, and AD6. ID₅₀ and ID₉₀ for BAT123 against HIV-I LA1 were 0.09 and 0.32 μg/ml, respectively.

Gauduin, M. C., Safrit, J. T., Weir, R., Fung, M. S., & Koup, R. A. (1995). Pre-and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. Journal of Infectious Diseases, 171(5), 1203-1209.

Figure 5 Postexposure protection by BAT-123 in vivo.

SCID mice reconstituted with human peripheral blood lymphocytes were inoculated with HIV-I LAb then BAT123 (I mg/kg) CD was given at various times (x axis). Titer of infectious HIV-I recovered from spleen cells at sacrifice 3-4 weeks later is indicated on y axis. Titer of<0.2 TCID/10⁶ splenocytes was considered negative. If either spleen or peritoneal lavage culture was positive, animal was considered infected with HIV-I.

Gauduin, M. C., Safrit, J. T., Weir, R., Fung, M. S., & Koup, R. A. (1995). Pre-and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. Journal of Infectious Diseases, 171(5), 1203-1209.

Figure 6 Therapeutic trial of BAT 123 in infected SCID mice reconstituted with human peripheral blood lymphocytes.

Two weeks after inoculation with 10 MID₅₀ of HIV-I LAI BAT 123 or control antibody (40 mg/kg) was given. Animals were sacrificed at times indicated (before antibody administration in 10, 2 weeks after antibody administration in 20), and titer ofinfectious HIV-I in spleens determined.

Gauduin, M. C., Safrit, J. T., Weir, R., Fung, M. S., & Koup, R. A. (1995). Pre-and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. Journal of Infectious Diseases, 171(5), 1203-1209.